共 50 条
- [21] Reduction in the need for glucocorticoids on the background of therapy with biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis: evidence from real clinical practice [J]. TERAPEVTICHESKII ARKHIV, 2024, 96 (05): : 465 - 470
- [24] Safety and Effectiveness of Biologic Disease-Modifying Antirheumatic Drugs in Older Patients with Rheumatoid Arthritis: A Prospective Cohort Study [J]. Drugs & Aging, 2020, 37 : 899 - 907
- [29] Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study [J]. Rheumatology and Therapy, 2021, 8 : 483 - 497
- [30] Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis [J]. KOREAN JOURNAL OF INTERNAL MEDICINE, 2024,